Key result
Cangrelor administration during flow diverter stenting in a pediatric patient with subarachnoid hemorrhage resulted in no ischemic or hemorrhagic complications.
Why the study?
Is cangrelor safe and effective for antiplatelet management in a pediatric patient undergoing acute flow diverter stenting for ruptured ICA aneurysm?
Case Report (n=1)
No
Is cangrelor safe and effective for antiplatelet management in a pediatric patient undergoing acute flow diverter stenting for ruptured ICA aneurysm?
Cangrelor can be successfully used as an acute antiplatelet agent during flow diverter stenting for ruptured aneurysms in pediatric patients.
Hypothesis-generating for cangrelor in pediatric acute flow diverter stenting; prospective studies needed before clinical adoption.
We herein report the case of a pediatric patient suffering from subarachnoid hemorrhage (SAH) due to a ruptured internal carotid artery (ICA) saccular aneurysm. Considering the unfavorable anatomy and irregular shape of the aneurysm, a flow diverter (FD) stent was positioned in addition to coils in an acute setting. Cangrelor (Kengreal, Chiesi, USA) IV bolus followed by maintenance IV infusion was administered in addition to ASA at the time of intervention. Transitioning from cangrelor to thienopyridine (clopidogrel) was done the day after the procedure without any ischemic or hemorrhagic complications. The patient was discharged symptom-free 24 days later. We discuss technical considerations focusing specifically on antiplatelet therapy management.
No takes yet. Share an insight, caveat, or question.
Russo et al. (2024) conducted a case report in Aneurysmal subarachnoid hemorrhage (n=1). Cangrelor was evaluated on Ischemic or hemorrhagic complications. Cangrelor administration during flow diverter stenting in a pediatric patient with subarachnoid hemorrhage resulted in no ischemic or hemorrhagic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: